JPRN-jRCT2031210432已完成1 期
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors
Tien Hoang0 个研究点目标入组 660 人开始时间: 2021年11月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •ECOG PS of Grade 0 or 1
- •- Adequate hematologic and end-organ function
- •- Histologic documentated locally advanced, recurrent, or metastatic malignancy
- •- Patients with confirmed availability of representative tumor specimens in formalin-fixed, paraffin-embedded (FFPE) blocks or more than 15 unstained slides
- •- Measurable disease according to RECIST v1.1
排除标准
- •- Leptomeningeal disease
- •- History of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on Screening chest computed tomograph (CT) scan
- •- History of autoimmune disease
- •- Positive human immunodeficiency virus (HIV) test
- •- Active hepatitis B or C, or tuberculosis
- •- Severe infection within 4 weeks prior to randomization
- •- Prior allogeneic bone marrow or solid organ transplant
- •- Significant cardiovascular disease
- •- Known clinically significant liver disease
研究者
相似试验
招募中
不适用
A Phase Ia/Ib Open Label, Dose-Escalation study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Tumors.NL-OMON55424Hoffmann-La Roche28
招募中
不适用
An Open-Label, Phase Ib, Dose*Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination with Bortezomib (Velcade®, PS-341) in Patients with Relapsed or Refractory Multiple Myeloma.M. KahlerPlasma Cell dyscrasia10035227NL-OMON31502Genentech26
招募中
1 期
A PHASE Ia/Ib STUDY OF STA551 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORSOCALLY ADVANCED OR METASTATIC SOLID TUMORSJPRN-jRCT2080225058Chugai Pharmaceutical Co., Ltd.233
招募中
1 期
A phase I study of ROSE12 alone and in combination with other anti-tumor agents in patients with solid tumorssolid tumorJPRN-jRCT2031230072Ajari Ifode219
招募中
不适用
A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RUNIMOTAMAB ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUAMB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS10027656Breast cancercancerNL-OMON54065Genentech Inc.20